依那普利联合丹参酮对急性加重期肺心病患者临床疗效及预后影响

Enalapril and Tanshinone on Acute Exacerbation of Clinical Curative Effect and Prognosis of Patients with Pulmonary Heart Disease

目的研究依那普利联合丹参酮治疗急性加重期肺心病的临床疗效及对患者预后的影响。方法将我院收治的100例急性加重期肺心病患者抽签随机分为观察组和对照组各50例,对照组单一采用依那普利治疗,观察组采取依那普利联合丹参酮治疗。比较两组临床疗效、血液流变学及心功能指标变化。结果观察组治疗总有效率为94.0%,显著高于对照组的78.0%,两组比较有统计学意义(P<0.05);治疗后观察组血浆黏度、红细胞压积、红细胞计数、纤维蛋白原显著降低,与对照组比较差异有统计学意义(P<0.05);治疗后观察组LVEF、SV、CO分别为62.64±6.54%、70.69±6.82ml、4.82±0.62L/min,高于对照组的57.69±5.24%、54.36±7.21ml、4.02±1.25L/min,对比差异显著,有统计学意义(P<0.05);两组均未见明显不良反应发生。结论依那普利联合丹参酮治疗急性加重期肺心病效果显著,可改善患者心功能,且安全性较高,具有较高的临床应用价值。

Objective To study the clinical therapeutic effects of enalapril combined with tanshi-none in the treatment of pulmonary heart disease in acute exacerbation and the influence on prognosis of the patients. Methods 100 patients were randomly divided into the observation group 〈br〉 （50cases） and the control group （50 cases）. The control group were treated with single enalapril while the observation group with enalapril combined with tanshinone. The clinical efficacy, hemorheology and cardiac function of the two groups were compared. Results The total effective rate of the observation group was 94% which was significantly higher than 78% of the control group（P〈0.05）; After the treatment, the plasma viscosity, hematocrit, red blood cell count and fib-rinogen decreased significantly and were significantly lower than those of the control group （P 〈0.05）; after the treatment, the LVEF, SV and CO of the observation group were （62.64 ±6.54）%, （70.69±6.82）ml and（4.82±0.62）L/min which was significantly higher than（57.69±5.24）%,（54.36±7.21） ml and（4.02±1.25）L/min of the control group and the difference was significant（P〈0.05）; there were no obvious adverse reactions in both two groups. Conclusion The effect of enalapril combined with tanshinone in treatment of pulmonary heart disease in acute exacerbation is remarkable. The treatment can improve the patients＆#39; cardiac function and is of high safety and high clinical appli-cation value.